Adagio Medical Holdings Inc is a medical device company that focuses on the development and commercialization of products for the treatment of cardiac arrhythmias. The company’s core technology is the proprietary Ultra Low Temperature Ablation platform known as ULTA. ULTA uses pressurized nitrogen gas cooled to near minus 196 degrees Celsius to create deep and durable lesions in ventricular myocardial tissue. The initial target indication for ULTA is ventricular tachycardia a life threatening arrhythmia originating in the heart’s ventricles. In the United States ventricular tachycardia associated sudden cardiac death accounts for approximately three hundred thousand deaths each year. Existing radio frequency ablation catheters were primarily designed for atrial fibrillation and are not optimized for the thicker ventricular myocardium where tissue depth often exceeds ten millimeters. Adagio’s purpose built catheter and console system called the vCLAS TM Cryoablation System is designed to deliver ULTA energy through an endocardial approach without the need for irrigation or tip contact force. The vCLAS system incorporates a nine French bi directionally deflectable catheter with a fifteen millimeter long ablation element and eight electrodes for intracardiac sensing and pacing. The company has obtained CE Mark approval for the vCLAS system in Europe and is pursuing FDA approval in the United States through the FULCRUM VT pivotal investigational device exemption study which completed enrollment in October 2025.

Adagio Medical Holdings Inc currently does not report product sales revenue as it remains in the pre commercial stage of its ULTA technology. The company has obtained CE Mark approval for the vCLAS TM Cryoablation System allowing it to market the device in European countries. This regulatory clearance creates a pathway for early revenue generation from sales to hospitals and electrophysiology labs in Europe once commercial distribution is established. In the United States Adagio is preparing to submit the results of the FULCRUM VT pivotal study to the FDA in the first half of 2026 seeking premarket approval for the vCLAS system. Upon FDA approval the company expects to begin selling its catheter and console system to U. S. healthcare providers. In addition to the first generation vCLAS system Adagio is developing a next generation vCLAS TM ULTRA catheter that requires only a single freeze and is compatible with standard 8.5 French sheaths aiming to improve workflow integration and usability. The company is also exploring a combined approach called pulsed field cryoablation PFCA which couples ULTA with pulsed field energy to potentially enhance lesion selectivity. Revenue will be derived from the sale of these hardware systems disposables and any associated service or support contracts. Until regulatory approvals are secured the firm’s financial activity consists primarily of research development expenses clinical trial costs and fundraising efforts.

Adagio Medical Holdings Inc occupies a specialized position within the electrophysiology device market where it seeks to address the unmet need for effective ventricular tachycardia ablation. The company competes against large established players such as Biosense Webster a division of Johnson & Johnson Abbott Medtronic and Boston Scientific which currently dominate the arena with radio frequency and pulsed field ablation catheters that were originally cleared for atrial fibrillation. These competitors offer products like the Biosense Webster Navistar Thermocool Deflectable catheter and the Abbott FlexAbility and Sensor Enabled catheters that have been adapted for ventricular tachycardia but are limited by shallow lesion depths typically five to six millimeters in healthy tissue and further reduced in scarred myocardium. Adagio’s Ultra Low Temperature Ablation technology differentiates itself by producing lesion depths that can exceed ten millimeters while maintaining a stable endocardial bond through cryoadhesion which eliminates the need for the physician to manually maintain tip contact during energy delivery. The absence of irrigation in the ULTA process reduces the risk of fluid overload and associated complications such as acute cardiac decompensation and steam pop formation. Additionally the ULTA platform allows physicians to titrate lesion depth by adjusting freeze duration providing a level of control not readily available with conventional radio frequency energy. Intellectual property protection further supports Adagio’s market position with a portfolio of eighty five issued patents and twenty five patent applications covering the core ULTA chemistry catheter designs console electronics and related manufacturing processes. This patent estate is intended to create a barrier to entry for competitors seeking to replicate the Ultra Low Temperature Ablation approach.

Adagio Medical Holdings Inc intends to serve hospitals cardiac electrophysiology laboratories and physicians who perform ventricular tachycardia ablation procedures. The company’s customers include academic medical centers community hospitals specialty heart clinics and group purchasing organizations that procure electrophysiology equipment for the treatment of patients with structural heart disease or idiopathic ventricular tachycardia. While the filing does not disclose specific customer names the target market consists of electrophysiologists and interventional cardiologists who require ablation tools capable of creating deep durable lesions in the ventricular myocardium to eliminate arrhythmogenic substrates. Adagio’s CE Mark approved vCLAS system is already eligible for sale in European markets allowing the company to engage with distributors hospital procurement teams and physician leaders in countries such as Germany France Italy Spain and the United Kingdom. Upon receiving FDA approval Adagio expects to expand its customer base to include United States hospital systems outpatient electrophysiology labs and private cardiology practices that perform VT ablation procedures. The company anticipates that reimbursement will be obtained through established Medicare and private payer pathways for catheter based ablation services similar to those currently available for radio frequency and pulsed field ablation procedures.